Free Trial Information
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

...exploit TCR-antigen pairings include Adaptive Biotechnologies Corp. (NASDAQ:ADPT), Pact Pharma Inc., TScan Therapeutics Inc. and 3T Biosciences Inc....
Read More
BioCentury | Aug 22, 2019
Emerging Company Profile

Tscan: Tracking down novel T cell targets

...which is testing a personalized neoantigen therapy in a trio of Phase I trials; and 3T Biosciences Inc....
...Fund, Novartis Venture Fund, Pitango HealthTech CEO: David Southwell Patents: Undisclosed Companies and Institutions Mentioned 3T Biosciences Inc....
Read More
Items per page:
1 - 2 of 2
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

...exploit TCR-antigen pairings include Adaptive Biotechnologies Corp. (NASDAQ:ADPT), Pact Pharma Inc., TScan Therapeutics Inc. and 3T Biosciences Inc....
Read More
BioCentury | Aug 22, 2019
Emerging Company Profile

Tscan: Tracking down novel T cell targets

...which is testing a personalized neoantigen therapy in a trio of Phase I trials; and 3T Biosciences Inc....
...Fund, Novartis Venture Fund, Pitango HealthTech CEO: David Southwell Patents: Undisclosed Companies and Institutions Mentioned 3T Biosciences Inc....
Read More
Items per page:
1 - 2 of 2